AIM ImmunoTech Inc. (AIM) News
Follow AIM ImmunoTech Inc. (AIM) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 25 public stories across 16 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video
Company highlights supportive survival observations, potential for biomarker-driven patient selection and upcoming Phase 2 DURIPANC milestonesAccess it hereOCALA, Fla., Sept. 30, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech I
NEWS | Sep 30, 2026, 12:49 PM UTC
H
Ai-Media Technologies Announces FY27 Guidance
Ai-Media Technologies Ltd ASX:AIM
NEWS | Sep 30, 2026, 01:25 AM UTC
L
Ai-Media Technologies Announces On-Market Share Buy-Back Of Up To 20.8 Million Shares
Ai-Media Technologies Ltd ASX:AIM
EQUITY | Sep 30, 2026, 01:25 AM UTC
L
AI-Media Technologies Targets 22-28% Recurring Revenue Growth for FY27
AI-Media Technologies ASX:AIM is targeting year-end annual recurring revenue (ARR) of between $44 million and $46m in the 2027 financial year, representing growth of about 22% to 28% from $36m at 30 June 2026.The AI-powe
EARNINGS | Sep 29, 2026, 11:38 PM UTC
L
Copernico Sim Approves Capital Increase For 4Timing Deal
Copernico SIM SpA MIL:COP
NEWS | Sep 25, 2026, 01:13 PM UTC
M
AIM ImmunoTech CEO letter outlines Ampligen role after daraxonrasib approval
AIM ImmunoTech said Ampligen’s differentiated mechanism may support a pancreatic-cancer role following FDA approval of daraxonrasib, citing retrospective survival data and targeting DURIPANC Phase 2 readouts in 2027.
EQUITY | Sep 22, 2026, 01:01 PM UTC
L
AIM ImmunoTech Converts ~$400,000 of Debt Into 1.75M Shares With Streeterville Capital
AIM ImmunoTech completed two debt-for-equity exchanges with Streeterville Capital on September 8 and 9, 2026, converting approximately $400,000 of principal from a November 18, 2025 promissory note into 1,749,434 shares
EQUITY | Sep 14, 2026, 08:47 PM UTC
M
AIM ImmunoTech converts $450,000 note into 1,921,441 shares
AIM ImmunoTech executed two debt-for-equity exchanges with Streeterville Capital on September 3 and 4, 2026, tied to its November 18, 2025 promissory note. Around $450,000 of principal was converted into 1,921,441 shares
MNA | Sep 10, 2026, 08:44 PM UTC
L
Aimia Inc publishes Schedule One update for AIM
The company filed an RNS announcement titled "Schedule One Update" on 10 September 2026.
EQUITY | Sep 10, 2026, 03:00 PM UTC
L
AIM - AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO
AIM - AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video
EQUITY | Sep 09, 2026, 01:03 PM UTC
L
AIM Aimia Inc issues Schedule One update via RNS
Aimia Inc has published a Schedule One update via an RNS announcement (RNS Number: 9078T), as provided by the London Stock Exchange news service.
EQUITY | Sep 08, 2026, 03:00 PM UTC
L
AI-Media Puts Multilingual AI at the Heart of the Broadcast Workflow at IBC2026
New LEXI Encoders, expanded LEXI Suite, LEXI Direct and partner integrations bring scalable AI-powered language capabilities into broadcast workflowsAI-Media Attending IBC 2026 - Booth 5.C34See how LEXI AD uses AI to cre
EQUITY | Sep 03, 2026, 10:07 AM UTC
L
Advance Information Marketing Malaysia 2026 4Q revenue, pre-tax loss
Advance Information Marketing Malaysia reported 4Q results for the quarter ended Jun 30 in MYR. 2026 revenue was 763,000 MYR versus 1,734,000 MYR in 2025, with pre-tax profit of -2,538,000 MYR.
EARNINGS | Sep 03, 2026, 09:06 AM UTC
L
AIM ImmunoTech expands Ampligen long COVID patent coverage through 2041
AIM ImmunoTech expands its Ampligen® global patent estate for long COVID protection in Europe and the United Kingdom through 2041.
EQUITY | Sep 02, 2026, 12:43 PM UTC
L
Morgans raises AIM price target for Ai-Media Technologies by 18%
Morgans raised its price target on Ai-Media Technologies (AIM) by 18% to A$0.26 per share.
EQUITY | Aug 27, 2026, 11:37 PM UTC
L
AIM - AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference
AIM - AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference
EQUITY | Aug 27, 2026, 01:08 PM UTC
L
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
EQUITY | Aug 27, 2026, 01:01 PM UTC
L
Ai-Media Technologies reports FY adjusted EBITDA of A$2.1M
Ai-Media Technologies posted FY adjusted EBITDA of A$2.1 million.
EQUITY | Aug 27, 2026, 01:36 AM UTC
H
AIM - AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article - Click For Relea
AIM - AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article
EQUITY | Aug 12, 2026, 12:44 PM UTC
H
AIM ImmunoTech Ahead on DURIPANC Trial
AIM ImmunoTech reaches critical clinical inflection point
EQUITY | Aug 03, 2026, 12:33 PM UTC
L
Great Western Mining Corporation PLC Announces Exercise of Warrants and Issue of Equity
DUBLIN, IRELAND / / July 3, 2026 / Great Western Mining Corporation PLC (AIM:GWMO)(ESM:8GW) announces that it ha
EQUITY | Jul 03, 2026, 11:30 AM UTC
L
Update on Intention to Move from AIM to Main Market
Reykjavík, July 03, 2026 (GLOBE NEWSWIRE) -- THIS ANNOUNCEMENT IS MADE FOR INFORMATION
EQUITY | Jul 03, 2026, 06:00 AM UTC
H
RTX CORP - RAYTHEON INCREASES AIM-9X MISSILE PRODUCTION CAPACITY TO 2500 PER YEAR
RTX CORP - RAYTHEON INCREASES AIM-9X MISSILE PRODUCTION CAPACITY TO 2500 PER YEAR
GEOPOLITICS | Jun 26, 2026, 12:01 PM UTC
M
AIM Outlines Milestones
AIM ImmunoTech outlines upcoming milestones, including DURIPANC primary endpoint analysis expected in December 2026
EARNINGS | Jun 24, 2026, 12:36 PM UTC